What does this research mean for the field?

Yiqihuoxue decoction protects against post-myocardial infarction injury and preserves mitochondrial function by activating cardiomyocyte PGC-1α expression via AMPK phosphorylation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 17, 2018BMC Complementary and Alternative MedicineOpen Access

Yiqihuoxue decoction protects against post-myocardial infarction injury via activation of cardiomyocytes PGC-1α expression

Q: What are the key findings of this study?

Yiqihuoxue decoction improved cardiac function and protected cardiomyocytes against hypoxia-induced injury by activating PGC-1α expression and maintaining mitochondrial functions via AMPK phosphorylation.

Q: What is the clinical evidence from this study?

Study design: Other. Population: Myocardial infarction (n=48). Intervention: Yiqihuoxue decoction (YQHX) vs. Vehicle (MI model) and Trimetazidine. Primary outcome: Cardiac function (LVEF, LVFS) and PGC-1α expression (p=<0.05).

View Full Paper

Ask AI

Bookmark

Key result

Yiqihuoxue decoction improves cardiac function and protects cardiomyocytes against hypoxia via AMPK-mediated PGC-1α activation.

P<0.05
n=48

Why the study?

The mechanisms by which Yiqihuoxue decoction affects PGC-1α expression and mitochondrial function in ischemic heart disease remain unclear.

Population

Myocardial ischemia rat model and ischemia/hypoxia injury model in H9c2 cardiomyocytes

Comparison

Yiqihuoxue decoction (8.2 g/kg) vs Sham, Model, and Trimetazidine (10 mg/kg)

Design

Randomized preclinical study

Follow-up

28 days

Authors

FLFanghe LiBeijing University of Chinese Medicine SGShuwen GuoBeijing University of Chinese Medicine CWChunguo WangBeijing University of Chinese Medicine

Discussion

Member takes

Implication

YQHX modulation of PGC-1α in rodent MI models; leaves open clinical translation and human trials.

Structured PICO

Population

48 adult male Sprague-Dawley rats subjected to myocardial infarction surgery and followed for 4 weeks to evaluate cardiac function and mitochondrial mechanisms.

Intervention

Yiqihuoxue decoction (YQHX) 8.2 g/kg in vivo

Comparator

Sham, Model (untreated), and Trimetazidine (10 mg/kg)

Outcome

Cardiac functions and morphology (in vivo); cell viability, LDH, ROS, and PGC-1α expression (in vitro)surrogate

Main Result

p-value: p=<0.05

Yiqihuoxue decoction protects against post-myocardial infarction injury by activating PGC-1α expression and maintaining mitochondrial function via AMPK phosphorylation.

Limitations

The mechanism by which YQHX regulates SIRT1 expression requires further study.
Other unidentified mechanisms may also contribute to the regulation of PGC-1α expression.

Cite This Study

Li et al. (2018) studied Myocardial infarction (n=48). Yiqihuoxue decoction (YQHX) vs. Vehicle (MI model) and Trimetazidine was evaluated on Cardiac function (LVEF, LVFS) and PGC-1α expression (p=<0.05). Yiqihuoxue decoction improved cardiac function and protected cardiomyocytes against hypoxia-induced injury by activating PGC-1α expression and maintaining mitochondrial functions via AMPK phosphorylation.

synapsesocial.com/papers/6aaa069081b585e3dc1bfdff https://doi.org/10.1186/s12906-018-2319-1

View Full Paper

Ask AI

Bookmark

Yiqihuoxue decoction protects against post-myocardial infarction injury via activation of cardiomyocytes PGC-1α expression

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Yiqihuoxue decoction protects against post-myocardial infarction injury via activation of cardiomyocytes PGC-1α expression

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider